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Abstract Phospholipase D has been recognized as playing an 
important role in signal transduction in many types of cells. We 
investigated the expression of phospholipase D during the 
differentiation of F9 embryonal teratocarcinoma cells. The 
ADP ribosylation factor-dependent phospholipase D activity, 
as measured by an in vitro assay, and H202-induced phospho- 
lipase D activity and phospholipase D protein content in whole 
cells were decreased uring the differentiation of F9 cells induced 
by a combination of dibutyryl cyclic AMP and ail-trans retinoic 
acid. In contrast, these changes were not observed when cells 
were induced by retinoic acid. These results suggest hat down- 
regulation of phospholipase D protein is associated with 
differentiation of F9 cells to a parietal endoderm lineage. 
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1. Introduction 
Phospholipase D (PLD) plays an important role in mem- 
brane lipid-mediated signal transduction. PLD catalyzes the 
hydrolysis of phospholipids, usually phosphatidylcholine 
(PC), to generate phosphatidic acid (PA) and choline. PA 
may act directly as a signaling molecule or can be further 
metabolized to form other messenger molecules, 1,2-diacylgly- 
cerol and lysophosphatidic a id. PLD has been implicated in a 
wide range of physiological processes and diseases including 
inflammation, secretion, mitogenesis, neuronal and cardiac 
stimulation, diabetes and the respiratory burst in neutrophils 
[1]. However, the precise role of PLD in cellular functions is 
still poorly understood. Mouse F9 teratocarcinoma cells have 
been used widely as a model system for the study of differ- 
entiation related to tumorigenesis and early events in the 
mouse development [2]. F9 stem cells show a very low sponta- 
neous differentiation. However, they can be differentiated into 
visceral extra-embryonic endoderm in response to retinoic 
acid (RA). Because cancer is a disease involving loss of cel- 
lular growth control and disruption of cell differentiation, 
there has been much interest in the role of RA in controlling 
patterns of gene expression during the differentiation of F9 
teratocarcinoma stem cells. RA is a strong tumor cell differ- 
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Abbreviations." PLD, phospholipase D; ARF, ADP ribosylation fac- 
tor; RA, retinoic acid; dbcAMP, dibutyryl cyclic AMP; GTPTS , gua- 
nosine 5'-O-(3-thiotriphosphate); PtdBut, phosphatidylbutanol 
entiation agent and has been used as an anti-cancer drug. On 
the other hand, when RA and dibutyryl cyclic AMP 
(dbcAMP) are added to culture media, F9 cells differentiate 
into a second phenotype that morphologically and biochemi- 
cally resembles parietal endoderm cells [3,4] which synthesize 
large quantities of extracellular matrix constituents including 
laminin, entactin and proteoglycan. Although the mechanism 
whereby RA regulates gene expression and differentiation is 
not completely understood, it is likely that high affinity RA 
receptor and/or cellular RA binding proteins are involved 
[5,6]. In addition, there might be a transmembrane signal 
transduction that provides, in part, a biochemical basis for 
the development of the RA-induced ifferentiation. 
It has been reported that expression of phospholipase C-7 
[7] or G-protein-coupled receptor [8] is negatively regulated in 
the differentiation of F9 teratocarcinoma stem cells into pari- 
etal endoderm. In the light of that work, PLD may be one of 
the intracellular signaling elements involved in the differentia- 
tion of F9 cells. Therefore, in order to examine the involve- 
ment of PLD during the differentiation of F9 cells, we inves- 
tigated the expression of PLD by a PLD activity assay and 
Western blot analysis during cell differentiation. I  the present 
study, we found that RA and dbcAMP reduced the ADP 
ribosylation factor 3 (ARF3)-dependent activation of PLD 
as well as H202-induced PLD stimulation during differentia- 
tion. Furthermore, protein levels of PLDI were also concom- 
itantly decreased uring differentiation i to parietal endo- 
derm, but only RA had no effect on the activity and 
expression of PLD during differentiation i to visceral endo- 
derm, suggesting that down-regulation f PLD relates to dif- 
ferentiation of F9 teratocarcinoma cells into parietal endo- 
derm. 
2. Materials and methods 
2.1. Materials 
Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum 
(FBS) and antibiotics were obtained from Gibco. dbcAMP and RA 
were from Sigma. Horseradish peroxidase-conjugated nti-rabbit IgG 
was from KPL. The ECL Western blotting detection kit was from 
Amersham. Anti-peptide antibody to PLDI was generated in rabbits 
using the C-terminal dodecapeptide of PLD1 coupled to keyhole lim- 
pet hemocyanin with glutaraldehyde. Human ARF3 was co-expressed 
with myristoyltransferase in Escherichia coli and purified using 
DEAE-Sephacel and Superdex 75 column chromatography as de- 
scribed by Weiss et al. [9]. 
2.2. Cell culture 
F9 cells were maintained in DMEM supplemented with 10% (v/v) 
FBS, 100 U/ml penicillin and 100 gg/ml streptomycin at 37°C in a 
humidified atmosphere of 5% CO2 and 95% air. Cells were cultured 
on plates pre-coated with 1% gelatin. 
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2.3. D(/fi~re~Ttiation (~f F9 celZv 
Differentiation into parietal endoderm was induced by addition of 
l0 7 M RA and 10 3 M dbcAMP to the medium. Cells were har- 
vested after 1, 2, 3 and 5 days of treatment. F9 cells were a/so difl'er- 
entiated into visceral endoderm by growing them in suspension in 
petri dishes with medium containing 10 7 M RA. RA-treated cells 
were harvested after 1, 2, 3 or 7 days. 
2.4. Measurement of  PLD activity in F9 cell lysates 
The cells were washed twice with buffer A (20 mM HEPES, pH 7.2, 
250 mM sucrose, 0.1 mM EDTA, 0.1 mM EGTA, 0.5 mM phenyl- 
methylsulfonyl fluoride) and resuspended in buffer A. The cells 
were lysed by 10 passes through a 27 gauge needle on ice. After 
unbroken cells and nuclei were removed by centrifugation at 900 ×g 
for 5 min, the resulting supernatant was used as the cell lysate for 
experiments. PLD activity was measured by the formation of 
[3H]phosphatidylbutanol (PtdBut) from [3H]palmitoyl-PC in the pres- 
ence of 1% butanol as described previously [4]. Phospholipid vesicles 
containing phosphatidylethanolamine/phosphatidylinositol 4,5-bis- 
phosphate/PC (16:1.4:1) were used as substrate [10]. 
2.5. hz vivo assay q[' PLD 
Undifferentiated or differentiated cells were serum-starved in 
DMEM for 24 h before the start of the assay. For the final 20 h of 
serum starvation, the cells were labelled with 1 paCi/ml [9,10-~H]- 
myristic acid. The ceils were washed and pre-incubated with 0.3% 
butane-l-ol t\~r 10 min. The cells were treated with H_,O_, for 30 min 
and PtdBut tbrmation was measured as described in [10.11]. Radio- 
activity incorporated into total phospholipids was measured and used 
to normalize the results. 
2.6. lmmunoprecipitation 
Cells treated with RA and dbcAMP for the indicated times were 
lysed with radio immunoprecipitation assay buffer (20 mM HEPES, 
pH 7.2, 1% Triton X-100, 1% deoxycholate, 0.1% SDS, 150 mM 
NaC1, 10 ~g/ml leupeptin, 10 ~ag/ml aprotinin, 1 mM phenylmethyl- 
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sulfonyl fluoride). After incubation for 30 min in an ice-bath, cells 
were completely broken by sonication and then, the lysate supernatant 
was pre-cleared by incubation with pre-immune IgG and protein A 
Sepharose for 30 min. Pre-cleared cell lysates were incubated with 
anti-PLD1 antibody and 30 ~tl of 50% slurry of protein A Sepharose 
for 4 h. The immune complex was collected by centrifugation and 
washed five times with an ice-cold buffer containing 20 mM Tris, 
pH 7.5, 1 mM EDTA, 1 mM EGTA, 150 mM NaC1, 2 mM Na3VO4, 
10% glycerol, 1% Nonidet P-40, followed by addition of SDS sample 
buffer and boiling. 
2. 7. Western blot anal),sLs" 
The recovered protein was resolved on a SDS-polyacrylamide g l 
electrophoresis (PAGE) gel and blotted to a PVDF membrane. The 
blot was probed with anti-PLD1 antibody, immunoreactive bands 
were visualized by chemiluminescence using horseradish peroxidase- 
conjugated anti-rabbit IgG and ECL reagent (Amersham). 
3. Result and discussion 
Al though it has been suggested that  PLD may be involved 
in cell growth and i f ferentiat ion [12 14], the relat ionship be- 
tween the expression of  PLD and cellular dif ferentiat ion has 
not been well elucidated. PLD activity has been shown to 
increase with granulocytic differentiation of  HL60 cells [15] 
and with differentiation of  rat C6 gl ioma cells to the astrocytic 
phenotype [16]. Several factors have been suggested to under-  
lie this increased activity [13,17], including changes in the 
amounts  o f  known PLD activators, such as PIP2, ARF  and 
Rho  family members  or protein kinase C, or in the level o f  
PLD mRNA.  However,  the most  stra ightforward possibi l ity 
that  protein levels o f  PLD itself are regulated dur ing differ- 
ent iat ion remains untested, since an ant ibody against PLD for 
Fig. 1. Morphological changes during the differentiation f F9 cells. F9 stem cells (0d) were differentiated into parietal endoderm (upper panel) 
by RA or into visceral endoderm (lower panel) by RA and dbcAMP as described in Section 2. Parietal endoderm cells treated for 1 (P-ld), 
2 (P-2d), 3 (P-3d) or 5 (P-5d) days; Visceral endoderm ceils treated for 1 (V-ld), 2 (V-2d), 3 (V-3d) or 7 (V-7d) days. 
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Fig. 2. Down-regulation of PLD during differentiation i to parietal 
endoderm of F9 cells. (A) F9 cells were incubated with RA and 
dbcAMP for the indicated periods of time. Cells were lysed and 
PLD activity in lysates was determined by measuring the ratio of 
formation of [3H]PtdBut and radioactivity incorporated into total 
phospholipid. (B) Cells treated without or with RA and dbcAMP 
for the indicated periods were labelled with [3H]myristate. The la- 
belled cells were pre-treated with vanadate (100 ~M) for 20 rain and 
then stimulated with 500 gM H202 for 20 min. The radioactivity in- 
corporated into PtdBut was measured as described in Section 2. (C) 
Cells treated with RA and dbcAMP for the indicated periods of 
time were lysed and immunoprecipitates (IP) were prepared using 
anti-PLDl antibody. The immunoprecipitates were then subjected to 
Western blotting with the same antfbody. 
Western blot analysis was not available. We have used the 
mouse F9 teratocarcinoma cell line to study the role of 
PLD expression during differentiation of F9 cells. F9 cells 
were progressively differentiated into parietal endoderm cells 
by treatment of RA/dbcAMP for 1, 2, 3 and 5 days and into 
visceral endoderm by treatment of RA for 1, 2, 3 and 7 days. 
Differentiation was monitored by morphological changes (Fig. 
1). Cellular aggregation in suspension cultm-es was typical for 
the visceral phenotype, while parietal endoderm often exhib- 
ited cellular processes [18]. Diffcrentiation was measured by 
an increase in the level of mRNA expression of laminin [19]. 
After exposure of F9 cells to RA/dbcAMP for various peri- 
ods, ARF3-dependent  PLD activity in the lysate of F9 cells 
was measured by using the exogenous ubstrate. In undiffer- 
entiated F9 cells, PLD activity was increased by addition of 
guanosine 5'-O-(3-thiotr iphosphate) (GTPTS) and ARF3 (Fig. 
2A). However, after 1 day of RA/dbcAMP treatment, a sig- 
nificant decrease of PLD activity was observed. It is known 
that morphological differentiation i to cells resembling parle- 
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Fig. 3. Regulation of PLD during the differentiation of visceral en- 
doderm. (A) Differentiation of F9 cells was induced with RA for 
the indicated periods of time. Cells were lysed and PLD activity in 
lysates was determined as described in Fig. 2. (B) Cells treated with 
RA for the indicated periods of time were lysed and immunoprecipi- 
tates (1P) were prepared using anti-PLD1 antibody. 'Mock' repre- 
sents a mock-precipitated control. The immunoprecipitates were 
then subjected to Western blotting with the same antibody. 
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tal endoderm is complete after 5 days of treatment with RA 
and dbcAMP. After treatment for 5 days, PLD activity, in 
response to recombinant ARF3, was greatly suppressed in our 
reconstitution assay in comparison to PLD activity in undif- 
ferentiated cells. Furthermore, we measured H202-induced 
PLD activation by labelling F9 cells with [3H]myristic acid. 
Recently, we reported that the combination of H202 and va- 
nadate stimulates PLD activity in Swiss 3T3 cells [20]. PLD 
activation was markedly increased by H202 and vanadate in 
undifferentiated F9 cells. However, while F9 cells differenti- 
ated into parietal endoderm cells with the treatment of RA/ 
dbcAMP, H202-induced PLD activation was abolished (Fig. 
2B). In contrast, changes in ARF-dependent PLD activity 
were not observed during differentiation into visceral endo- 
derm (Fig. 3A). These results demonstrate that PLD activity 
decreased uring differentiation of F9 cells into parietal endo- 
derm but not into visceral endoderm. There are several pos- 
sibilities that can interpret his finding and one of them deals 
with the change of the level of PLD protein itself. In order to 
analyze the relationship between the induction of differentia- 
tion and PLD expression in F9 cells, we examined the protein 
level of PLD during the different stages of differentiation. 
Immunoprecipitation and Western blot analysis revealed 
that the expression level of PLD decreased ramatically after 
1 day of RA/dbcAMP treatment and was barely detectable 
after 5 days (Fig. 2C). Thus, the decrease in PLD activity in 
the differentiated cells is most likely due to the decreased level 
of PLD protein. Taken together, our results, obtained by a 
PLD activity assay, immunoprecipitation a d Western blot- 
ting by anti-PLDl antibody, indicate that PLD is down-regu- 
lated during RA/dbcAMP-induced ifferentiation. In contrast, 
the protein level of PLD showed no significant changes after 
treatment with RA which differentiates F9 cells into visceral 
endoderm (Fig. 3B). To investigate PLD down-regulation i  a 
transcriptional context, we examined the level of PLD mRNA 
by Northern blot analysis. However, the level of PLD mRNA 
was below the threshold of detectability. Recently, in contrast 
to our results, it has been reported that GTPTS-dependent 
PLD activity increased time-dependently during differentia- 
tion of C6 cells induced by dbcAMP [16] and HL60 cells 
induced by RA/dbcAMP [15]. A different regulation of PLD 
isozymes during differentiation of cells may be due to cell type 
specificity. In conclusion, we have found that the level of PLD 
protein markedly decreased uring RA/dbcAMP-induced if- 
ferentiation. From these results, it may be assumed that 
down-regulation f PLD could be an important step in differ- 
entiation of F9 cells by RA/dbcAMP. 
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